Focused On-demand Library for Keratin, type II cytoskeletal 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P04264

UPID:

K2C1_HUMAN

Alternative names:

67 kDa cytokeratin; Cytokeratin-1; Hair alpha protein; Keratin-1; Type-II keratin Kb1

Alternative UPACC:

P04264; B2RA01; P85925; P86104; Q14720; Q6GSJ0; Q9H298

Background:

Keratin, type II cytoskeletal 1, also known as Keratin-1, plays a pivotal role in the structural integrity of epithelial cells. It is part of a complex network of proteins that form the cytoskeleton, providing resilience and strength to the skin and hair. Alternative names include 67 kDa cytokeratin and Hair alpha protein, highlighting its significance in various biological structures.

Therapeutic significance:

Keratin-1 is implicated in several dermatological disorders, such as Epidermolytic hyperkeratosis and Ichthyosis hystrix, Curth-Macklin type. These conditions underscore the protein's critical role in skin health. Understanding the role of Keratin, type II cytoskeletal 1 could open doors to potential therapeutic strategies, offering hope for individuals suffering from these debilitating skin diseases.